Lisette Hilton
Lisette Hilton, president of Words Come Alive, has written about health care, the science and business of medicine, fitness and wellness for 25 years. Visit www.WordsComeAlive.com.
Sharing is caring: Millennial patients and social media
Not only is the selfie generation happy to share, but they could be the secret to social media success.
Ingredients in eczema topicals pose contact dermatitis risk
Ingredients used in topical products used to relieve atopic dermatitis in children might put those patients at higher risk for contact dermatitis.
Gout patients at 60% greater risk for stone disease
Men and women with gout are at 60% greater risk for nephrolithiasis than adults without gout, according to a study looking at not only the chronic kidney condition’s incidence but also potential risk factors for first-time nephrolithiasis in people with and without gout.
Demystifying vulvovaginal beauty
According to one expert, these are the top 5 things that bother women about their feminine parts.
Wrinkle scales: To use or not to use?
Wrinkle classifications systems are often used in research to quantify wrinkles after treatment, but do they have a place in clinical practice?
HA fillers and blindness
Are we still in the dark when it comes to preventing and managing blindness from filler injections?
Risky business
This month we’re profiling dermatologist Eric Schweiger, M.D., who owns 24 practices in New York and New Jersey. Find out more about this young entrepreneur.
Lymph-node dissection increases rates of regional disease control
Lymph-node dissection is not associated with increased melanoma survival. Surgery may be best option to decrease risk for recurrence. A positive sentinel node does not automatically lead to complete dissection
Gene therapy trial for blistering skin condition advancing to next stage
Gene therapy trial for blistering skin condition advancing to next stage
FCX-007 could be the first major medical advance for recessive dystrophic epidermolysis bullosa, or RDEB, in decades.
Relief from the itch in atopic dermatitis
An experimental drug designed to control itching in people with moderate-to-severe AD shows promise in early trial.

Poll